Acute migraine therapy: New drugs and new approaches

Current Treatment Options in Neurology

Volumn 13, Issue 1, 2011, Pages 1-14

  Monteith, Teshamae S ^a   Goadsby, Peter J ^a  

^a UCSF Headache Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; DIHYDROERGOTAMINE; ERGOTAMINE; GLUTAMATE RECEPTOR; KAINIC ACID RECEPTOR; MAP 0004; NITRIC OXIDE SYNTHASE; NXN 188; OLCEGEPANT; PLACEBO; PROSTANOID RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; TELCAGEPANT; TEZAMPANEL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ZOLMITRIPTAN;

ARTICLE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INTERMETHOD COMPARISON; MIGRAINE; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 79551544583     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0105-6     Document Type: Article

References (69)

1. Wolff H: Headache and Other Head Pain. New York: Oxford University Press; 1948.
2. KL Hoskin H Kraube PJ Goadsby 1996 Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study Brain 119 249 256 10.1093/brain/119.1.249 8624686 (Pubitemid 26077569)
3. V Limmroth A May Auerbach, et al. 1996 Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine J Neurol Sci 138 1-2 60 65 1:CAS:528: DyaK28Xkslymtro%3D 10.1016/0022-510X(95)00344-2 8791240 (Pubitemid 26194276)
4. SK Afridi MS Matharu L Lee, et al. 2005 A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate Brain 128 4 932 939 1:STN:280:DC%2BD2M7lsV2jug%3D%3D 10.1093/brain/awh416 15705611 (Pubitemid 40516929)
5. S Evers J Afra A Frese, et al. 2009 EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force Eur J Neurol 16 9 968 981 1:STN:280:DC%2BD1Mrot1Cksw%3D%3D 10.1111/j.1468-1331.2009.02748.x 19708964
6. PJ Goadsby RB Lipton MD Ferrari 2002 Migraine-current understanding and treatment N Engl J Med 346 4 257 270 1:CAS:528:DC%2BD38XmslGgsQ%3D%3D 10.1056/NEJMra010917 11807151 (Pubitemid 34438866)
7. P Tfelt-Hansen G Block C Dahlof, et al. 2000 Guidelines for controlled trials of drugs in migraine: second edition Cephalalgia 20 9 765 786 1:STN:280:DC%2BD3M3isFahsg%3D%3D 10.1046/j.1468-2982.2000.00117.x 11167908 (Pubitemid 32154559)
8. DW Dodick G Sandrini P Williams 2007 Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine CNS Drugs 21 1 73 82 1:CAS:528:DC%2BD2sXislClur8%3D 10.2165/00023210-200721010-00006 17190530
9. PP Humphrey 1991 5-Hydroxytryptamine and the pathophysiology of migraine J Neurol 238 Suppl 1 S38 S44 10.1007/BF01642905 2045830
10. YE Knight L Edvinsson PJ Goadsby 1999 Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122, 288 Neuropeptides 33 1 41 46 1:CAS:528: DyaK1MXjsVyit7Y%3D 10.1054/npep.1999.0009 10657470 (Pubitemid 29248963)
11. JF Pregenzer GL Alberts WB Im, et al. 1999 Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands) Br J Pharmacol 127 2 468 472 1:CAS:528:DyaK1MXjs1yqsb8%3D 10.1038/sj.bjp.0702532 10385247 (Pubitemid 29245685)
12. SJ Peroutka 2005 Neurogenic inflammation and migraine: implications for the therapeutics Mol Interv 5 5 304 311 1:CAS:528:DC%2BD2MXhtlaisLbJ 10.1124/mi.5.5.10 16249526 (Pubitemid 41595462)
13. DJ Goldstein KI Roon WW Offen, et al. 2001 Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial Lancet 358 1230 1234 1:CAS:528:DC%2BD3MXnslWmsrw%3D 10.1016/S0140- 6736(01)06347-4 11675061 (Pubitemid 33010848)
14. U Reuter AJ Pilgrim HC Diener, et al. 2009 COL-144, a selective 5-HT1F agonist, for the treatment of migraine attacks Cephalalgia 29 122
15. U Arulmani A Maassenvandenbrink CM Villalón PR Saxena 2004 Calcitonin gene-related peptide and its role in migraine pathophysiology Eur J Pharmacol 500 1-3 315 330 1:CAS:528:DC%2BD2cXotFCksrw%3D 10.1016/j.ejphar.2004. 07.035 15464043 (Pubitemid 39304018)
16. PJ Goadsby L Edvinsson R Ekman 1988 Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system Ann Neurol 23 193 196 1:CAS:528:DyaL1cXhsVeqsLo%3D 10.1002/ana.410230214 2454066
17. PJ Goadsby L Edvinsson R Ekman 1990 Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann Neurol 28 2 183 187 1:STN:280:DyaK3M%2FisVSktQ%3D%3D 10.1002/ana.410280213 1699472 (Pubitemid 20244522)
18. J Olesen HC Diener IW Husstedt, et al. 2004 Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N Engl J Med 350 11 1104 1110 1:CAS:528:DC%2BD2cXitV2qur0%3D 10.1056/NEJMoa030505 15014183 (Pubitemid 38298990)
19. TW Ho MD Ferrari DW Dodick 2008 Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372 9656 2115 2123 1:CAS:528:DC%2BD1cXhsFajs7nE 10.1016/S0140-6736(08)61626-8 19036425 CGRP antagonists are important acute anti-migraine compounds comparable to the triptans with nonvasoconstrictive properties.
20. AP Andreou PJ Goadsby 2009 Therapeutic potential of novel glutamate receptor antagonists in migraine Expert Opin Investig Drugs 18 6 789 803 1:CAS:528:DC%2BD1MXmtlWqtrg%3D 10.1517/13543780902913792 19426123 This is a good review of glutamate receptor antagonists.
21. MA Kai-Kai R Howe 1991 Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat Histochem J 23 4 171 179 1:STN:280:DyaK38%2FosVGgug%3D%3D 10.1007/BF01046588 1684179
22. QP Ma 2001 Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats Neuroreport 12 8 1589 1591 1:CAS:528: DC%2BD3MXkvVOjtLw%3D 10.1097/00001756-200106130-00015 11409721
23. AP Andreou RJ Storer PR Holland PJ Goadsby 2006 CNQX inhibits trigeminovascular neurons in the rat: a microiontophoresis study Cephalalgia 26 11 1383
24. CN Sang NM Ramadan RG Wallihan, et al. 2004 LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine Cephalalgia 24 7 596 602 1:STN:280:DC%2BD2cvit12kug%3D%3D 10.1111/j.1468-2982.2004.00723.x 15196302 (Pubitemid 39272960)
25. AP Andreou PR Holland PJ Goadsby 2009 Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation Br J Pharmacol 157 3 464 473 1:CAS:528: DC%2BD1MXnt1Ggtrw%3D 10.1111/j.1476-5381.2009.00142.x 19309356
26. RJ Storer PJ Goadsby 1999 Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors Neuroscience 90 4 1371 1376 1:CAS:528:DyaK1MXisFKitbs%3D 10.1016/S0306-4522(98) 00536-3 10338304 (Pubitemid 29170152)
27. Anttila V, Stefansson H, Kallela M, et al.: Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010, 42(10):869-873. The minor allele of rs1835740 is the first common susceptibility variant implicated in migraine without aura.
28. A Szallasi DN Cortright CA Blum, et al. 2007 The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept Nat Rev Drug Discov 6 5 357 372 1:CAS:528:DC%2BD2sXkslyiu7Y%3D 10.1038/nrd2280 17464295 (Pubitemid 46705200)
29. M Hou R Uddman J Tajti, et al. 2002 Capsaicin receptor immunoreactivity in the human trigeminal ganglion Neurosci Lett 330 3 223 226 1:CAS:528:DC%2BD38XntVWrsbY%3D 10.1016/S0304-3940(02)00741-3 12270633 (Pubitemid 35254040)
30. M Cui P Honore C Zhong, et al. 2006 TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists J Neurosci 26 37 9385 9393 1:CAS:528:DC%2BD28XhtVSlu77J 10.1523/JNEUROSCI.1246-06.2006 16971522 (Pubitemid 44396851)
31. PJ Goadsby 2007 Emerging therapies for migraine Nat Clin Pract Neurol 3 11 610 619 1:CAS:528:DC%2BD2sXht1CnsrzI 10.1038/ncpneuro0639 17982431 (Pubitemid 350048227)
32. Summ O, Akerman S, Holland PR, Goadsby PJ: The TRPV1 receptor antagonist, A-993610, shows no effect on neurogenic dural dilation but is able to block capsaicin induced dilation [abstract PO325]. Presented at 14th Congress of International Headache Society. Philadelphia, PA; September 10-13, 2009. Cephalalgia 2009, 29(s1):136.
33. GA Lambert JB Davis JM Appleby, et al. 2009 The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission Naunyn Schmiedebergs Arch Pharmacol 380 4 311 325 1:CAS:528:DC%2BD1MXhtFOitbfN 10.1007/s00210-009-0437-5 19690836
34. J Olesen LL Thomsen H Iversen 1994 Nitric oxide is a key molecule in migraine and other vascular headaches Trends Pharmacol Sci 15 5 149 153 1:CAS:528:DyaK2cXksl2ltbs%3D 10.1016/0165-6147(94)90075-2 7538702 (Pubitemid 24156497)
35. EP Wei MA Moskowitz P Boccalini HA Kontos 1992 Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles Circ Res 70 6 1313 1319 1:CAS:528:DyaK38XkvVeis7Y%3D 1576743
36. SK Afridi H Kaube PJ Goadsby 2004 Glyceryl trinitrate triggers premonitory symptoms in migraineurs Pain 110 3 675 680 1:CAS:528: DC%2BD2cXmt1WrsLo%3D 10.1016/j.pain.2004.05.007 15288408 (Pubitemid 39036799)
37. GG Schoonman J van der Grond C Kortmann, et al. 2008 Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3 T magnetic resonance angiography study Brain 131 Pt 8 2192 2200 1:STN:280: DC%2BD1cvps1WltQ%3D%3D 10.1093/brain/awn094 18502781
38. KL Hoskin DC Bulmer PJ Goadsby 1999 Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME Neurosci Lett 266 3 173 176 1:CAS:528: DyaK1MXjsVSgtLg%3D 10.1016/S0304-3940(99)00281-5 10465701 (Pubitemid 29249243)
39. LH Lassen M Ashina I Christiansen, et al. 1997 Nitric oxide synthase inhibition in migraine Lancet 349 9049 401 402 1:STN:280:DyaK2s7osFOqtg%3D%3D 10.1016/S0140-6736(97)80021-9 9033475 (Pubitemid 27077677)
40. J De Alba NM Clayton SD Collins, et al. 2006 GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain Pain 120 1-2 170 181 16360270
41. Palmer JE, Guillard FL, Laurijssens BE, et al.: A randomized, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine [abstract PC.18]. Presented at the European Headache and Migraine Trust International Congress 2008. London, UK; September 4-7, 2008. Cephalalgia 2009, 29(1):129.
42. Medve RA, Andrews JS: Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura [abstract PC.23]. Presented at the European Headache and Migraine Trust International Congress 2008. London, UK; September 4-7, 2008. Cephalalgia 2009. 29(1):126.
43. Medve RA, Lategan TW: A phase 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled study of NXN-188 dihydrochloride in acute migraine without aura. [abstract 190]. Presented at the 2nd European Headache and Migraine Trust International Congress 2010. Nice, France; October 28-31, 2010. J Headache Pain 2010, 11(1):38.
44. M De Felice M Ossipov R Wang 2010 Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers Brain 133 2475 2488 20627971
45. DW Jenkins W Feniuk PP Humphrey 2001 Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones Br J Pharmacol 134 6 1296 1302 1:CAS:528:DC%2BD3MXosl2qsLk%3D 10.1038/sj.bjp.0704357 11704650
46. P Sarchielli A Alberti M Codini, et al. 2000 Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks Cephalalgia 20 10 907 918 1:STN:280:DC%2BD3MvntlSgsg%3D%3D 10.1046/j.1468-2982.2000.00146.x 11304026 (Pubitemid 32336718)
47. CR Lin F Amaya L Barrett, et al. 2006 Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity J Pharmacol Exp Ther 319 3 1096 1103 1:CAS:528:DC%2BD28Xht1yltL%2FP 10.1124/jpet.106.105569 16966471
48. KA Maubach RJ Davis DE Clark, et al. 2009 BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache Br J Pharmacol 156 2 316 327 1:CAS:528:DC%2BD1MXpt1Wlsr4%3D 10.1111/j.1476-5381.2009.00027.x 19154437
49. Diaz-Insa S, Goadsby PJ, Zanchin G, et al.: Early treatment with almotriptan allows a good outcome even in allodynic migraine patients: an Act when Mild (AwM) substudy [abstract PC.02]. Presented at the European Headache and Migraine Trust International Congress 2008. London, UK; September 4-7, 2008. Cephalalgia 2009, 29(1):119.
50. SD Silberstein WB Young 1995 Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology Neurology 45 3 Pt 1 577 584 1:STN:280:DyaK2M3gs1Gmsw%3D%3D 7898722
51. S Markowitz K Saito MA Moskowitz 1988 Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache Cephalalgia 8 2 83 91 1:STN:280:DyaL1c3psFWitg%3D%3D 10.1046/j.1468-2982.1988.0802083.x 3401921
52. GA Lambert AJ Lowy P Boers, et al. 1992 The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids Brain Res 597 321 330 1:CAS:528:DyaK3sXhtFKmt7k%3D 10.1016/0006-8993(92)91489-2 1473003 (Pubitemid 23003702)
53. PJ Goadsby AL Gundlach 1991 Localization of 3 H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine Ann Neurol 29 1 91 94 1:CAS:528:DyaK3MXksVWkt74%3D 10.1002/ana.410290116 1996883
54. JR Saper S Silberstein 2006 Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine Headache 46 Suppl 4 S171 S181 10.1111/j.1526-4610.2006.00601.x 17078849 (Pubitemid 44656902)
55. Silberstein SD, Kori SH, Tepper SJ, et al.: Efficacy and tolerability of MAP0004, a novel orally inhaled therapy, in treating acute migraine [abstract PO04]. Presented at 14th Congress of International Headache Society. Philadelphia, PA; September 10-13, 2009. Cephalalgia 2009, 1(s1):12.
56. JL Brandes RK Cady FG Freitag, et al. 2007 Sumatriptan-naproxen for acute treatment of migraine: a randomized trial JAMA 297 13 1443 1454 1:CAS:528:DC%2BD2sXjvFCjt74%3D 10.1001/jama.297.13.1443 17405970 (Pubitemid 46556470)
57. Goldstein J, Pugach N, Smith TR: Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan [abstract PO23]. Presented at 14th Congress of International Headache Society. Philadelphia, PA; September 10-13, 2009. Cephalalgia 2009, 29(s1):20.
58. JL Brandes RK Cady FG Freitag, et al. 2009 Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use Headache 49 10 1435 1444 10.1111/j.1526-4610.2009.01530.x 19849720
59. Lance JW, Goadsby PJ: Mechanisms and Management of Headache, edn 7th. Philadelphia, PA: Elsevier Butterworth Heinemann; 2005:153.
60. P Winner AD Rothner R Nett, et al. 2000 A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents Pediatrics 106 5 989 997 1:STN:280: DC%2BD3M%2FlvVKgtQ%3D%3D 10.1542/peds.106.5.989 11061765
61. SL Linder NT Mathew RK Cady, et al. 2008 Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial Headache 48 9 1326 1336 10.1111/j.1526-4610.2008.01138.x 18484981
62. S Evers A Rahmann C Kraemer, et al. 2006 Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen Neurology 67 3 497 499 1:CAS:528:DC%2BD28Xntl2msbo%3D 10.1212/01.wnl.0000231138.18629.d5 16775229 (Pubitemid 44214980)
63. J Afra A Cecchini PS Sandor 2000 Comparison of visual and auditory evoked cortical potentials in migraine patients between attacks Clin Neurophysiol 111 6 1124 1129 1:STN:280:DC%2BD3c3os1OntQ%3D%3D 10.1016/S1388-2457(00)00271-6 10825720 (Pubitemid 30316352)
64. M Denuelle N Fabre G Geraud 2008 Posterior cerebral hypoperfusion in migraine without aura Cephalalgia 28 8 856 862 1:STN:280:DC%2BD1cvnslaisA%3D%3D 10.1111/j.1468-2982.2008.01623.x 18513260 This interesting study suggests that migraine without aura may share a mechanism similar to that of migraine with aura
65. Holland PR, Schembri C, Fredrick J, Goadsby PJ: Transcranial magnetic stimulation for the treatment of migraine aura? [abstract PO29]. Presented at 14th Congress of International Headache Society. Philadelphia, PA; September 10-13, 2009. Cephalalgia 2009, 29(s1):22.
66. H Bolay U Reuter AK Dunn, et al. 2002 Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model Nat Med 8 2 136 142 1:CAS:528:DC%2BD38Xht1equrc%3D 10.1038/nm0202-136 11821897 (Pubitemid 34155124)
67. AW Hauge MS Asghar HW Schytz, et al. 2009 Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study Lancet Neurol 8 8 718 723 1:CAS:528:DC%2BD1MXpvFentL0%3D 10.1016/S1474-4422(09)70135-8 19570717
68. RB Lipton DW Dodick SD Silberstein, et al. 2010 Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial Lancet Neurol 9 4 373 380 10.1016/S1474-4422(10)70054-5 20206581
69. Beth Israel Deaconess Medical Center: Phase 2 study of the effect of transcranial direct current stimulation (tDCS) on pain and headache frequency in migraine. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Cited 2010 Nov 9. Available from: http://clinicaltrials.gov/ct2/ show/NCT00521196. NLM Identifier: NCT00521196.